A Prospective Evaluation of Contrast Sensitivity and Disability Glare in Refractive Surgery, a Sub-Study of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

March 31, 2008 updated by: Walter Reed Army Medical Center
The purpose of this study is to conduct a prospective assessment of small target contrast sensitivity and disability glare in refractive surgery. Study subjects will undergo the treatment of their choice (PRK or LASIK) and will be evaluated before and after treatment. Evaluations will include best corrected visual acuity, uncorrected visual acuity, psychometric questionnaire, pupil size, biomicroscopic examination, manifest refraction, wavefront measurements, low contrast acuity, and contrast sensitivity at normal and at low luminance with and without disability glare.

Study Overview

Study Type

Interventional

Enrollment

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • District of Columbia
      • Washington, District of Columbia, United States, 20307
        • Walter Reed Army Medical Center, Center For Refractive Surgery

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Informed consent.
  • Normal, healthy active adults with access to medical care at Walter Reed Health Care System.
  • Age 21 years or older.
  • Spherical equivalent of the manifest refractive error between -1.0 to -6.0 diopters (D), inclusive, with no more than 3.0D of cylinder. The absolute value of the cylinder (expressed in minus cylinder) will be limited such that the short axis of the elliptical ablation will be no smaller than 4.9mm. The following specifies the maximum cylinder for a given spherical component of the manifest refraction:

Spherical component / Maximum cylinder

  • 1.0D / -0.5D
  • 2.0D / -1.0D
  • 3.0D / -1.5D
  • 4.0D / -2.0D
  • 5.0D / -2.5D
  • 6.0D / -3.0D
  • Corrected vision of at least 20/20
  • Soft contact lens users must havE removed their lenses at least two weeks prior to baseline measurements.
  • Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least four weeks prior to baseline measurements. At least two weekly manifest refractions and keratometry measurements will be required in this interval. The last two measurements must not vary by more than 0.50D in any meridian.
  • Patients undergoing orthokeratology must have their lenses removed at least 6 months prior to the baseline examination. At least two monthly manifest refractions and keratometry measurements taken after the third month out of lenses must not vary by more than 0.50D in any meridian.
  • Refractive stability must be documented by previous refractions. Spherical and cylindrical portion of the manifest refraction must not have varied by more than 0.50D over the previous 12 months.
  • Exhibits strong motivation for keeping the follow-up visits.
  • Available for evaluation at Walter Reed during the two-year follow-up period.
  • Service members must have their command approval to participate in the study.
  • Access to transportation to meet follow-up requirements.

Exclusion Criteria:

  • Residual, recurrent or active ocular diseases or corneal abnormalities in either eye such as iritis, uveitis, keratoconjunctivitis sicca, herpetic keratitis, vernal conjunctivitis, lagophthalmos, corneal scarring, glaucoma, previous steroid responder, occludable chamber angles, visually significant cataracts.
  • Either one or both eyes suffering from chronic dryness.
  • Taking any systemic medications that may affect wound healing such as corticosteroids or antimetabolites.
  • Patient corneal neovascularization within one mm of the ablation zone.
  • History of any previous eye surgery, including previous refractive surgery.
  • Best corrected visual acuity of less than 20/20.
  • Progressive myopia or keratoconus.
  • Any systemic disease that may affect wound healing, such as connective tissue disorders (rheumatoid arthritis, systemic lupus erythematosus, etc.), diabetes, or severe atopic disease.
  • Any physical or mental impairment that would preclude participation in any of the examinations.
  • For contact lens users there must be no evidence of contact lens corneal warpage on computerized topography.
  • Currently on flight status or projected to be on flight status within ten years.
  • Pregnant or breast-feeding an infant. Women of childbearing age must take a urine blood pregnancy test before starting this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: KRAIG S. BOWER, MD, Walter Reed Army Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted

December 19, 2006

First Submitted That Met QC Criteria

December 19, 2006

First Posted (Estimate)

December 20, 2006

Study Record Updates

Last Update Posted (Estimate)

April 1, 2008

Last Update Submitted That Met QC Criteria

March 31, 2008

Last Verified

March 1, 2008

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • WRAMC WU 3 04-2335-99f

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe